stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) P/B ratio
As of 5 November 2026, Denali Therapeutics Inc. (DNLI) trades at a P/B ratio of 4.0×. Over the past ten years it has ranged from 0.0× (December 2017) to 11.4× (December 2020); the current reading is higher than 62% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2023 | 2.9× | (14.34%) |
| FY2022 | 3.3× | (40.93%) |
| FY2021 | 5.6× | (29.00%) |
| FY2020 | 7.9× | 88.10% |
| FY2019 | 4.2× | 20.53% |
| FY2018 | 3.5× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 4.2× | (27.13%) |
| Jun 2026 | 5.8× | 102.40% |
| Dec 2023 | 2.9× | 17.01% |
| Sep 2023 | 2.4× | (28.52%) |
| 22 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | n/m |
| CELC Celcuity, Inc. compare | n/m |
| IDYA IDEAYA Biosciences, Inc. compare | 2.9× |
| ELVN Enliven Therapeutics, Inc. compare | 3.3× |
| DNLI Denali Therapeutics Inc. | 4.0× |
| DYN Dyne Therapeutics, Inc. compare | 4.1× |
| VKTX Viking Therapeutics, Inc. compare | 5.2× |
| VRDN Viridian Therapeutics, Inc. compare | 5.5× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 30.1× |
| Biotechnology industry median | 2.0× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on DNLI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement